- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01461278
Multicenter Investigation of the Glaukos® Suprachoroidal Stent Model G3 In Conjunction With Cataract Surgery
May 18, 2022 updated by: Glaukos Corporation
A Prospective, Randomized, Single-Masked, Controlled, Parallel Groups, Multicenter Clinical Investigation of the Glaukos® Suprachoroidal Stent Model G3 In Conjunction With Cataract Surgery
Evaluate the safety and efficacy of the Glaukos® Suprachoroidal Stent Model G3 in conjunction with cataract surgery, compared to cataract surgery only, in subjects with mild to moderate primary open-angle glaucoma.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is an IDE trial to evaluate the safety and efficacy of the Glaukos® Suprachoroidal Stent Model G3 (hereinafter referred to as G3) in conjunction with cataract surgery, compared to cataract surgery only, in subjects with mild to moderate primary open-angle glaucoma.
Study Type
Interventional
Enrollment (Actual)
505
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Wisconsin
-
Racine, Wisconsin, United States, 53405
- Eye Centers of Racine and Kenosha
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
45 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Mild to moderate open-angle glaucoma
- Characteristics consistent with mild to moderate glaucoma
- Use of one (1) to three (3) medications at time of screening exam
Exclusion Criteria:
- Pigmentary or pseudoexfoliative glaucoma
- Prior incisional glaucoma surgery
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Cataract surgery plus iStent supra
|
Cataract surgery alone
Cataract surgery and implantation of one iStent supra
|
|
Active Comparator: Cataract surgery
|
Cataract surgery alone
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
≥ 20% Reduction in Intraocular Pressure (IOP)
Time Frame: Baseline and Month 24
|
Baseline and Month 24
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Diurnal IOP Reduction from Baseline
Time Frame: Baseline and Month 24
|
Baseline and Month 24
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 22, 2011
Primary Completion (Actual)
March 13, 2019
Study Completion (Actual)
March 12, 2020
Study Registration Dates
First Submitted
October 25, 2011
First Submitted That Met QC Criteria
October 26, 2011
First Posted (Estimate)
October 28, 2011
Study Record Updates
Last Update Posted (Actual)
May 19, 2022
Last Update Submitted That Met QC Criteria
May 18, 2022
Last Verified
May 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GC-007
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Open-angle Glaucoma
-
Omar SaidCompletedGlaucoma,Primary Open-Angle ,Primary Angle ClosureEgypt
-
Henry Ford Health SystemNot yet recruitingPrimary Open Angle Glaucoma (POAG) | Secondary Open Angle Glaucoma | Open Angle Glaucoma (OAG)United States
-
Peking UniversityRecruitingPrimary Open Angle Glaucoma | Ocular Hypertension | Primary Open Angle Glaucoma of Both Eyes | Primary Open-Angle Glaucoma, Unspecified Eye | Suspect GlaucomaChina
-
Glaucot Teknoloji Anonim SirketiCompletedPrimary Open-Angle GlaucomaTurkey
-
China Medical University HospitalCompletedEffect of Acupuncture on Visual Acuity and Visual Field in Patients With Primary Open-angle GlaucomaPrimary Open-angle GlaucomaTaiwan
-
InnFocus Inc.CompletedPrimary Open-angle GlaucomaSpain, United States, United Kingdom, France, Italy
-
Glaukos CorporationTerminatedPrimary Open-Angle GlaucomaUnited States
-
Rehab mahmoud abdelhamid mohamedCairo UniversityCompletedPrimary Open-angle GlaucomaEgypt
-
Cairo UniversityUniversity of LuebeckUnknown
-
Xiaodong ZhouCompletedPrimary Open-angle Glaucoma
Clinical Trials on Cataract surgery
-
Iladevi Cataract and IOL Research CenterCompletedCataract Surgery | Shallow Anterior Chamber | PhacoemulsificationIndia
-
Zagazig UniversityCompleted
-
University of OklahomaCompletedPrimary Open Angle Glaucoma | Cataract | Pigmentary GlaucomaUnited States
-
Technolas Perfect Vision GmbHCompletedCataractCzech Republic, India
-
Ziemer Ophthalmic Systems AGCompleted
-
Technolas Perfect Vision GmbHCompleted
-
Technolas Perfect Vision GmbHCompletedCataractCzech Republic, India
-
Glaukos CorporationCompletedOpen-Angle GlaucomaUnited States
-
Guy's and St Thomas' NHS Foundation TrustCompletedCataract | Surgery
-
University Hospital, BordeauxCompleted